Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines-Reference-Cited by-同舟云学术

Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines

Published:2022-01-24 Issue:4 Volume:21 Page:453-469
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

McFall-Boegeman Hunter¹²^ORCID,Huang Xuefei¹²³

Affiliation:

1. Department of Chemistry, Michigan State University, 48824 East Lansing, Michigan, USA

2. Institute for Quantitative Health Science and Engineering, Michigan State University, 48824 East Lansing, Michigan, USA

3. Department of Biomedical Engineering, Michigan State University, 48824, East Lansing, Michigan, USA

Funder

the National Institutes of Health

Michigan State University

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2022.2029415

Reference182 articles.

1. Pandemic influenza vaccine manufacturing process and timeline: World Health Organization; 2009 [cited 2019 May 6]. Available from: https://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/

2. Cloned Viral Protein Vaccine for Foot-and-Mouth Disease: Responses in Cattle and Swine

3. Recent Advances in Subunit Vaccine Carriers

4. Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins

5. Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunizing Mice with Influenza Virus-like Particles Expressing the Leishmania amazonensis Promastigote Surface Antigen Alleviates Inflammation in Footpad;Vaccines;2024-07-18

2. Tumor‐Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano‐Vaccine for Overcoming Immune Barriers for Effective and Long‐Term Cancer Immunotherapy;Advanced Healthcare Materials;2024-06-11

3. Toward innovative veterinary nanoparticle vaccines;Animal Diseases;2024-05-10

4. Optimized production of full-length PCV2d virus-like particles in Escherichia coli: A cost-effective and high-yield approach for potential vaccine antigen development;Microbial Pathogenesis;2024-05

5. Unlocking cancer vaccine potential: What are the key factors?;Human Vaccines & Immunotherapeutics;2024-04-02